February 24, 2026 - BY Admin
The last two years changed the global conversation on sickle cell treatment. Gene therapies were approved internationally, and Nigeria recorded major progress through the LUTH and Sickle Cell Foundation Nigeria bone marrow transplant programme. Hope is rising, but access, eligibility, cost and safety questions remain central.
What changed globally
In December 2023, the United States FDA approved two cell-based gene therapies for sickle cell disease in eligible patients aged 12 and older. One uses CRISPR gene-editing technology, while the other uses a gene-addition approach. These approvals were historic because they shifted the conversation from lifelong symptom management to potential functional cures for selected patients.
However, gene therapy is complex. It can involve months of preparation, stem cell collection, chemotherapy and specialised monitoring. It is not a simple injection and it is not suitable for everyone. Cost and infrastructure also make access difficult in many countries.
For Nigeria, the lesson is not to create unrealistic promises. The lesson is to invest in local capacity, research, counselling, ethical communication and equitable access.
- Gene therapy is promising but highly specialised.
- Patients need careful eligibility assessment.
- Cost and access remain major equity concerns.
- Nigeria needs local research, training and infrastructure.
Nigeria's bone marrow transplant progress
Nigeria's most important local development has been the SCFN/LUTH bone marrow transplant programme. Reports from 2024 to 2026 described the programme as a major step toward making curative treatment available at home for selected sickle cell patients.
Bone marrow or stem cell transplantation is an established potential cure for sickle cell disease when a patient is eligible and has a suitable donor. It also requires specialist teams, donor matching, preparation, infection control, post-transplant follow-up and long-term monitoring.
The LUTH and SCFN progress matters because it can reduce dependence on medical tourism and build Nigerian expertise. It also highlights the need for counselling so families understand both possibilities and risks.
- Not every sickle cell patient is eligible for transplant.
- A compatible donor is usually required.
- The process requires specialised preparation and follow-up.
- Families should avoid unverified cure claims.
What NGOs should communicate responsibly
Sickle cell advocacy must balance hope with accuracy. It is harmful to tell every warrior that a cure is immediately available, affordable or risk-free. It is also harmful to ignore progress that can inspire investment and policy action.
Favoured NGO can help by translating treatment news into plain language, directing families to credible specialists, raising funds for care support and advocating for stronger local capacity.
The future of sickle cell care in Nigeria should include newborn screening, hydroxyurea access where prescribed, safe blood transfusion systems, pain care, mental health support, transplant capacity and research.
- Use the phrase "potential cure for eligible patients" rather than blanket cure claims.
- Encourage consultation with haematologists.
- Reject miracle-cure misinformation.
- Advocate for equitable access to advanced care.
Frequently Asked Questions
Is gene therapy available to every sickle cell patient?
No. Gene therapy is highly specialised and eligibility depends on age, disease severity, clinical history and the treatment centre.
Is bone marrow transplant a cure?
It is an established potential cure for selected patients, but it carries risks and requires expert evaluation and follow-up.
How Favoured NGO Can Help
Favoured, the Lord Delights in You Foundation supports sickle cell awareness, genotype education, community outreach, counselling and care advocacy in Nigeria. Families, schools, churches, mosques, youth groups and community leaders can contact us for sensitisation programmes, partnership opportunities and support referrals.